Skip to main content

Table 2 Reduction in the occurrence of dermatologic changes in dogs with generalized demodicosis after treatment with either Bravectoor Advocate®

From: Efficacy of orally administered fluralaner (BravectoTM) or topically applied imidacloprid/moxidectin (Advocate®) against generalized demodicosis in dogs

Bravecto : occurrence of lesions on days before and after treatment (dogs were treated on Day 0: number of dogs/number of dogs per group)

Clinical sign

Day −4

Day 28

Day 56

Day 84

Erythematous patches

62.5% (5/8)

37.5% (3/8)

12.5% (1/8)

12.5% (1/8)

Crusts, casts or scales

100% (8/8)

62.5% (5/8)

62.5% (5/8)

12.5% (1/8)

Advocate®; occurrence of lesions on days before and after initial treatment (dogs were treated on Days 0, 28 and 56 a : number of dogs/number of dogs per group)

Clinical sign

Day −4

Day 28

Day 56

Day 84

Erythematous patches

87.5% (7/8)

50% (4/8)

0% (0/8)

0% (0/7)b

Crusts, casts or scales

100% (8/8)

100% (8/8)

37.5% (3/8)

42.9% (3/7)b

  1. aSkin assessments were performed before treatment.
  2. bOn day 59 one dog had to be euthanized due to the presence of a malign tumour in the stomach.